Cargando…

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

This study investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital. 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the resea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponticelli, Domenico, Madotto, Fabiana, Conti, Sara, Antonazzo, Ippazio C., Vitale, Andrea, Della Ragione, Giovanni, Romano, Maria L., Borrelli, Mario, Schiavone, Beniamino, Polosa, Riccardo, Ferrara, Pietro, Mantovani, Lorenzo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505466/
https://www.ncbi.nlm.nih.gov/pubmed/34637084
http://dx.doi.org/10.1007/s11739-021-02857-y
_version_ 1784581538524954624
author Ponticelli, Domenico
Madotto, Fabiana
Conti, Sara
Antonazzo, Ippazio C.
Vitale, Andrea
Della Ragione, Giovanni
Romano, Maria L.
Borrelli, Mario
Schiavone, Beniamino
Polosa, Riccardo
Ferrara, Pietro
Mantovani, Lorenzo G.
author_facet Ponticelli, Domenico
Madotto, Fabiana
Conti, Sara
Antonazzo, Ippazio C.
Vitale, Andrea
Della Ragione, Giovanni
Romano, Maria L.
Borrelli, Mario
Schiavone, Beniamino
Polosa, Riccardo
Ferrara, Pietro
Mantovani, Lorenzo G.
author_sort Ponticelli, Domenico
collection PubMed
description This study investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital. 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins. Adverse events following immunization (AEFI) were reported. Two weeks after the first dose anti-SARS-CoV-2 antibodies exceeded reactivity cut-off in 82.5% the participants. Four HCWs tested positive at nasopharyngeal swab after 3 months. More than three-quarters reported AEFIs. Our findings offer an insight regarding the vaccine response after 3 months from its administration, with a special focus on effectiveness data, as well as the type and number of AEFIs complained by HCW recipients. The presented study may serve as reference for future research which will be necessary to explore the long-term safety of this vaccine, especially in population at high risk for infection, such as HCWs.
format Online
Article
Text
id pubmed-8505466
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85054662021-10-12 Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up Ponticelli, Domenico Madotto, Fabiana Conti, Sara Antonazzo, Ippazio C. Vitale, Andrea Della Ragione, Giovanni Romano, Maria L. Borrelli, Mario Schiavone, Beniamino Polosa, Riccardo Ferrara, Pietro Mantovani, Lorenzo G. Intern Emerg Med Im - Original This study investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital. 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins. Adverse events following immunization (AEFI) were reported. Two weeks after the first dose anti-SARS-CoV-2 antibodies exceeded reactivity cut-off in 82.5% the participants. Four HCWs tested positive at nasopharyngeal swab after 3 months. More than three-quarters reported AEFIs. Our findings offer an insight regarding the vaccine response after 3 months from its administration, with a special focus on effectiveness data, as well as the type and number of AEFIs complained by HCW recipients. The presented study may serve as reference for future research which will be necessary to explore the long-term safety of this vaccine, especially in population at high risk for infection, such as HCWs. Springer International Publishing 2021-10-12 2022 /pmc/articles/PMC8505466/ /pubmed/34637084 http://dx.doi.org/10.1007/s11739-021-02857-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Im - Original
Ponticelli, Domenico
Madotto, Fabiana
Conti, Sara
Antonazzo, Ippazio C.
Vitale, Andrea
Della Ragione, Giovanni
Romano, Maria L.
Borrelli, Mario
Schiavone, Beniamino
Polosa, Riccardo
Ferrara, Pietro
Mantovani, Lorenzo G.
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
title Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
title_full Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
title_fullStr Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
title_full_unstemmed Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
title_short Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
title_sort response to bnt162b2 mrna covid-19 vaccine among healthcare workers in italy: a 3-month follow-up
topic Im - Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505466/
https://www.ncbi.nlm.nih.gov/pubmed/34637084
http://dx.doi.org/10.1007/s11739-021-02857-y
work_keys_str_mv AT ponticellidomenico responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT madottofabiana responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT contisara responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT antonazzoippazioc responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT vitaleandrea responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT dellaragionegiovanni responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT romanomarial responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT borrellimario responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT schiavonebeniamino responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT polosariccardo responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT ferrarapietro responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup
AT mantovanilorenzog responsetobnt162b2mrnacovid19vaccineamonghealthcareworkersinitalya3monthfollowup